Drug plant effluent breeds resistance while complying fully with discharge limits

Nikhil Singh
2 Min Read
Ijede Rd Ikorodu Pharmaceuticals Factory For Crsterlight Overseas Agency Ltd Nigeria 1985 Designed by Michael Olutusen Onafowokan Foundation Details Production Buildn Drwg209-Pb-S2 024. Photo: Onafowokan Michael Olutusen, licensed CC BY-SA 4.0 via Wikimedia Commons.

Hyderabad – Around 30 per cent of India drug exports are manufactured around Hyderabad, and researchers have repeatedly found antibiotic concentrations in local water bodies approaching therapeutic doses.

Water carrying antibiotics at those levels does not merely pollute. It applies sustained selective pressure on bacteria, which is the precise condition under which resistance evolves.

Why this is different from ordinary effluent

Most industrial pollution harms locally and in proportion to concentration. Antibiotic effluent creates resistant organisms, and organisms travel. A resistant strain selected in a drain outside a manufacturing plant does not stay there.

The harm therefore falls on patients who never lived near the plant, in hospitals on other continents, through the loss of drugs that used to work. It is among the clearest cases of a cost imposed entirely outside the transaction that created it.

Where the regulation stops short

Pharmaceutical plants making active ingredients are already subject to zero liquid discharge requirements, and effluent standards are being extended to micropollutants.

But conventional discharge limits measure oxygen demand, solids and metals. They were never designed to detect antibiotic residues at the concentrations that matter for resistance, so a plant can comply fully with its consent conditions while discharging effluent that drives resistance.

Procurement is the available lever

The National Action Plan on antimicrobial resistance takes a One Health approach spanning human and animal use. One proposal with real teeth is preferential weighting in government tenders for manufacturers that demonstrate zero liquid discharge and treat effluent to remove antibiotic residues.

Buyers, including European health systems purchasing Indian generics, can apply the same test. For listed pharmaceutical companies, this sits at the intersection of the water footprint attribute and product responsibility, and it is not yet a question most investors ask.

Source: Published research on pharmaceutical effluent and antimicrobial resistance in Hyderabad, and the National Action Plan on Antimicrobial Resistance.

Share This Article
Follow:
Nikhil Singh is a Senior Correspondent at The ESG India, covering ESG, CSR, sustainability and government policy across India. He reports on corporate accountability, climate action and social impact.